• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Henry Schein rises before hours on Street-beating Q4, updated guidance

Henry Schein rises before hours on Street-beating Q4, updated guidance

February 15, 2022 By Sean Whooley

Henry ScheinHenry Schein (NSDQ:HSIC) shares ticked up this morning on fourth-quarter results that topped the consensus forecast.

The Melville, New York-based company posted profits of $147.2 million, or $1.05 per share, on sales of $3.3 billion for the three months ended Dec. 25, 2021, for a 3.2% bottom-line gain on sales growth of 5.2%.

Adjusted to exclude one-time items, earnings per share were $1.07, 16¢ ahead of Wall Street, where analysts were looking for sales of $3.1 billion.

Henry Schein’s dental sales increased by 9.4% year-over-year, although the company’s $1.1 billion in medical sales represented a 3.2% dip from 2021. Excluding sales of personal protective equipment (PPE) and COVID-19-related products, sales increased by 3.6%, as PPE and COVID-19-related products were in higher demand this time last year, according to a news release.

“Despite the impact of the global COVID-19 pandemic, we are pleased to report excellent full-year 2021 financial results, including an outstanding fourth quarter that exceeded our expectations,” Henry Schein Chairman and CEO Stanley M. Bergman said in the release. “We have updated our 2022 financial guidance based on this latest view of our businesses.

“The updated guidance reflects the execution of two key strategic priorities contained in our 2022 to 2024 strategic plan: continuous operational improvement in our distribution businesses leading to exceptional customer experience and profit improvement, complemented by increasing the overall contribution of our technology and value-added services businesses and our dental specialty products, which have higher sales growth and higher operating margins.”

Henry Schein said it now expects to log GAAP diluted EPS of between $4.75 and $4.91 in 2022, representing growth between 7% and 10% compared to the company’s GAAP diluted EPS in 2021. It also represents growth of 5% to 9% over Henry Schein’s 2021 adjusted EPS.

HSIC shares were up 1.6% at $77 per share in pre-market trading today.

Filed Under: Business/Financial News, Dental, Featured, MassDevice Earnings Roundup, Wall Street Beat Tagged With: Henry Schein

More recent news

  • Alpheus Medical raises $52M for ultrasound-activated tumor therapy
  • Elucent Medical wins FDA breakthrough nod for in-body spatial intelligence system
  • EndoQuest Robotics completes first cases in pivotal surgical robot trial
  • Study links Abbott CGM use to lower risk of hospitalizations due to heart complications
  • Intuitive Surgical is making a CEO change

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at [email protected].

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy